The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork

• Sponsor: Lv Yingjuan (Other)
• Overall Status: Completed
• CT.gov ID: NCT02638181
• Collaborator: (none)
• Enrollment: 60
• Location: 1
• Arm: 1
• Duration (Months): 29
• Patients Per Site Per Month: 2.1

Study Details

Study Description

Brief Summary

This study was to assess the distinct expression of matrix metalloproteinase 13,tissue inhibitor of metalloproteinases 3, and calcium-sensing receptor, in human trabecular meshwork between normal and glaucomatous eyes.The expressions of matrix metalloproteinase 13, tissue inhibitor of metalloproteinases 3 and calcium-sensing receptor in the trabecular meshwork tissues were examined by streptavidin-peroxidase immunohistochemical staining method and western blot, and histological changes of trabecular meshwork were studied by Hematoxylin and Eosin staining.

Condition or Disease	Intervention/Treatment	Phase
Open-angle Glaucoma	Procedure: trabeculectomy	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 60 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: The Expression of Matrix Metalloproteinase 13（MMP13）, Tissue Inhibitor of Metalloproteinases 3（TIMP13）, and Calcium-sensing Receptor（CaSR） in Human Trabecular Meshwork
• Study Start Date: Jul 1, 2013
• Actual Primary Completion Date: Dec 1, 2015
• Actual Study Completion Date: Dec 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: trabeculectomy	Procedure: trabeculectomy

Outcome Measures

Primary Outcome Measures

1. the expressions of matrix metalloproteinase 13 and calcium-sensing receptor [one hour after operation]

Secondary Outcome Measures

1. histological changes of trabecular meshwork [one hour after operation]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 50 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• intraocular pressure greater than 22 mmHg with two or more medications

• wide anterior chamber angle

• glaucomatous optic neuropathy (Glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect

• visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry

Exclusion Criteria:

• the presence of any secondary form of glaucoma including exfoliation syndrome or a history of ocular trauma, etc

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Tianjin Medical University Eye Hospital	Tianjin	Tianjin	China	300384

Sponsors and Collaborators

• Lv Yingjuan

Investigators

• Study Director: xiaorong li, Tianjin Medical University Eye Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Lv Yingjuan, department of ophthamology, Tianjin Medical University Eye Hospital
• ClinicalTrials.gov Identifier: NCT02638181
• Other Study ID Numbers: tjykdxykyy3
• First Posted: Dec 23, 2015
• Last Update Posted: Jan 10, 2017
• Last Verified: Jan 1, 2017

• Keywords provided by Lv Yingjuan, department of ophthamology, Tianjin Medical University Eye Hospital: matrix metalloproteinase 13; tissue inhibitor of metalloproteinases 3; calcium-sensing receptor; trabecular meshwork; open-angle glaucoma
• Additional relevant MeSH terms: Glaucoma; Glaucoma, Open-Angle

Study Results

No Results Posted as of Jan 10, 2017